Analystreport

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Smith Barney Citigroup from $40.00 to $63.00.

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations